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Until recently, there has been an ongo-
ing worldwide quest in search for
disease-specific molecular biomarkers
in medicine. These biological molecules
can allow for: a reliable and accurate
disease diagnosis and prognosis, bet-
ter understanding of pathogenesis and
pathophysiological mechanisms, and for
predicting disease progression and moni-
toring therapy. Furthermore, biomarkers
can provide major opportunities for
drug target identification which can ulti-
mately translate into new therapeutic
strategies with disease-modifying effects.
Notably, all of these conditions are inher-
ent characteristics of neuropsychiatric
diseases.
Biomarker research has achieved great
success in various clinical fields such
as cardiovascular disease, hepatic dis-
orders, neurotrauma leading to key
markers including the discovery of tro-
ponin as marker for myocardial infarction,
and 14-3-3 protein for Creuzfolt-Jacob
Disease, S100β/UCH-L1/αII-spectrin for
brain trauma (Hayes et al., 2011; Kobeissy
et al., 2011; Mondello et al., 2011).
However, in psychiatry this field is still
lagging since no putative biomarker has
yet made its way into clinical application
(Schulenborg et al., 2006; Lescuyer et al.,
2007).
Biological psychiatry research has
been introduced as an attempt to draw
psychiatry back to its biological roots in
order to improve injury mechanisms and
disease processes and its components. It
has been well-understood today in clini-
cal medicine that no promising accurate
and definite disease diagnosis, therapy,
and prognosis can be established without
drawing back the clinical manifestation
of the disease. Therefore, biological psy-
chiatry is now focusing on the use of all
available advanced molecular techniques
that can allow for biomarker detection
assisted by the afore-employed imaging
and analysis techniques. Such approaches
include the utilization of high through-
put omics approaches such as: epigenetics,
genomics, proteomics, lipidomics, and
metabolomics studies (Robeva, 2010;
Westerhoff, 2011). In addition, these
methodologies rely on sophisticated
computational-multi disciplinary field
of systems biology utilizing advanced
bioinformatics processing tools that can
interpret the high throughput molecular
omics data relevant to neuropsychi-
atric research. Among the ultimate aims
of such discipline is the identification
of novel sensitive and disease-specific
biomarker(s).
The promise that systems biology can
lead a progress in biological psychia-
try returns to the very complex nature
of psychiatric disorders. Such disorders
involve multifactorial genetic and envi-
ronmental interactions together with the
dynamic nature of protein alterations
affecting both cellular as well as structural
changes on the neuronal levels. Therefore,
assessing psychiatric disorders cannot be
targeted at a single behavioral or cel-
lular level but rather would require a
holistic global approach that can assess
different components of such disorders
(Fang and Casadevall, 2011; Westerhoff,
2011). This can lead the inquiry into
the roots of such disorders and identify
new diagnostic and assessment biomark-
ers. However, the need for biomarker dis-
covery and the implementation of sys-
tems biology techniques is not just because
of the complexity of the disease. It is
also an attempt to surmount the avail-
able diagnostic techniques such as DSM
IV and ICD-10 that involve “subjective”
checklist analysis of signs and symp-
toms of these diseases that causes frustra-
tion among most psychiatric practition-
ers (Linden, 2012; Tretter and Gebicke-
Haerter, 2012).
Having been said, there has been
a pronounced worldwide joint effort
in the advancing of biomarker stud-
ies that is evident by the surge of
research and review articles focusing
on the application of systems biology,
bioinformatics, and biomarkers in neu-
ropsychiatry. These studies have included
the use of high-throughput genomic, epi-
genetics, proteomic, metabolomics, and
other—bioinformatic computational algo-
rithms tools as well as the use of animal
models, in vitro and in vivo tissue cultures
and in silico models. These techniques
have been applied on different aspects of
neuropsychiatric disorders spanning: drug
abuse, eating disorders, and other psy-
chiatric disorders involving schizophrenia,
bipolar disorder, and major depressive dis-
order etc. (Kobeissy et al., 2008; Avena,
2011).
The application of these techniques
has provided several disease models of
psychiatric diseases (Tretter and Gebicke-
Haerter, 2012) that have moved research
and therapy forward as with the dopamine
agonist model of schizophrenia that
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we reviewed in a separate publication
(Alawieh et al., 2012). However, suc-
cess reported by using such techniques
is still in its infancy due to the afore-
mentioned complexity of psychiatric
diseases as well as for other reasons. These
include, on one hand, the limitations
associated with these techniques cou-
pled with “mindset” related to scientists
and researchers that emphasizes on data
discovery rather than data analysis and val-
idation. This resulted in massive amount
of data—majorly non-replicable and
non-validated—with very low biological
significance and clinical impact (Kraemer
et al., 2002; Staner, 2006; Martins-De-
Souza et al., 2011). Therefore, there is
now an uprising need for the integrative
and predictive analysis as well as vali-
dation of the available data collected to
infer the biological significance relevant to
psychiatry.
Finally, the field of biomarker discov-
ery in psychiatry, taking advantage of sys-
tems biology approach and the available
bioinformatics tools, is believed to yield
several advantages including early diagno-
sis that is critical to psychiatric diseases
and accurate criteria for disease, diagno-
sis, classification, and stratification. It can
also allow for advanced personalized ther-
apy and can act, if appropriately, validated
as surrogate end points that can eliminate
several limitations and greatly advance
clinical research (Biomarkers Definitions
Working Group, 2001; Zhang et al.,
2010).
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